Leif Johansson

Pascal Soriot

Jean-Philippe Courtois

Marcus Wallenberg

Marc Dunoyer

Rudy Markham

Bruce Burlington

Baroness Shriti Vadera

Geneviève Berger

Graham Chipchase

Ann Cairns

Dr Cornelia (Cori) Bargmann

Useful Links

Get in touch

Vox Markets Podcast

AstraZeneca Plc

AstraZeneca posted a spike in full-year revenues and earnings on Tuesday, boosted by strong demand for its cancer drugs, and forecast further growth in the current year.

Annual sales, profits jump at AstraZeneca

Drugmaker Astrazeneca said on Monday that its gastric and gastroesophageal junction cancer treatment, Imfinzi, has been recommended for approval in the European Union by the Committee for Medicinal Products for Human Use (CHMP).

Astrazeneca's Imfinzi receives EU recommendation from CHMP

AstraZeneca on Monday reported mixed regulatory and clinical news, with its breast cancer drug Enhertu securing a US breakthrough therapy designation in early disease, while a late-stage lung cancer trial of ceralasertib in combination with Imfinzi failed to meet its primary survival endpoint.

AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles

Drugmaker AstraZeneca chalked up two regulatory wins on Tuesday, with approvals in both the US and Europe for key treatments in oncology and immunology.

AstraZeneca chalks up dual regulatory wins in cancer and immunology

AstraZeneca is to invest $2bn ramping up manufacturing facilities in Maryland, America, the blue chip drugs giant said on Monday.

AstraZeneca to spend $2bn in US manufacturing push

Drugmaker AstraZeneca said on Tuesday that its Koselugo asset has been approved for usage in the European Union for the rare, progressive, genetic condition, plexiform neurofibromas, in adults with neurofibromatosis type 1.

AstraZeneca's Koselugo receives EU approval

Drugmaker AstraZeneca said on Wednesday that its chronic rhinosinusitis with nasal polyps treatment, Tezspire, has been approved in the European Union as an add-on therapy with intranasal corticosteroids for adults.

Astrazeneca's Tezspire secures EU approval

AstraZeneca has received the green light from European regulators for its Saphnelo treatment for lupus, the pharma giant announced on Monday.

AstraZeneca lupus treatment gets EU approval

Deutsche Bank downgraded AstraZeneca to 'sell' from 'hold' on Thursday and cut the price target to 10,500p from 11,500p as it said it was turning sceptical on SERENA-4.

Deutsche Bank downgrades AstraZeneca to 'sell'

Drugmaker AstraZeneca said on Tuesday that Baxdrostat had met its primary endpoint in the Bax24 Phase III trial, delivering a "statistically significant and clinically meaningful reduction" in 24-hour ambulatory systolic blood pressure in patients with resistant hypertension.

AstraZeneca's Baxdrostat hits Phase III endpoint in resistant hypertension

Anglo-Swedish drugs giant AstraZeneca is to list directly on the New York Stock Exchange, it was announced on Monday.

AstraZeneca to list in New York, retain London listing

AstraZeneca slumped on Monday after saying it was pausing plans to invest £200m at its Cambridge research site.

AstraZeneca to pause £200m Cambridge investment, shares slump

Drugmaker Astrazeneca said on Tuesday that "strong growth momentum" had continued in H1, with "excellent R&D pipeline delivery" in the year-to-date.

Astrazeneca H1 gross profits up 10pc as 'strong growth momentum' continues

AstraZeneca announced on Thursday that its investigational treatment 'gefurulimab' achieved statistically significant and clinically meaningful results in a phase three trial for generalised myasthenia gravis (gMG), a rare autoimmune neuromuscular disorder.

AstraZeneca reports positive results from autoimmune treatment trial

Drugmaker AstraZeneca said on Tuesday that it plans to invest $50.0bn in the US for medicines manufacturing and R&D by 2030.

AstraZeneca to invest $50bn in US manufacturing and R&D

An investigational AstraZeneca treatment for amyloidosis has failed to show a statistical significance in late-stage trials, the blue chip pharmaceutical group said on Wednesday.

AstraZeneca drug fails to meet main goal in late-stage amyloidosis trial

Analysts at Berenberg raised their target price on drugmaker AstraZeneca from £140 to £142 per share on Wednesday, citing "strong pipeline readouts" which were yet to be reflected in its share price.

Berenberg raises target price on AstraZeneca

Drugmaker AstraZeneca said on Friday that its Imfinzi asset has been approved in the EU as the first and only perioperative immunotherapy for muscle-invasive bladder cancer.

AstraZeneca's Imfinzi gets EU green light

Drugmaker AstraZeneca's Datroway has been approved in the US for adult patients with previously treated advanced EGFR-mutated non-small cell lung cancer.

AstraZeneca's Datroway gets green light from FDA

Drugmaker AstraZeneca revealed on Friday that it has entered a strategic research collaboration with Chinese firm CSPC Pharmaceuticals Group.

AstraZeneca launches strategic research collaboration with China's CSPC Pharmaceuticals

Drugmaker AstraZeneca said on Friday that it had received approval from the European Commission for fixed-duration regimens of its chronic lymphocytic leukaemia candidate Calquence in a first-line setting.

AstraZeneca's Calquence receives European Commission approval

EU regulators have recommended AstraZeneca's Imfinzi for approval in the treatment muscle-invasive bladder cancer (MIBC).

AstraZeneca Plc

Latest Coverage

Annual sales, profits jump at AstraZeneca

Astrazeneca's Imfinzi receives EU recommendation from CHMP

AstraZeneca gets fresh designation for Enhertu while Imfinzi trial fizzles

AstraZeneca chalks up dual regulatory wins in cancer and immunology

Overview

Company Profile

Classification